We have previously shown that two consecutive substitutions leaded to consecutive nonsense mutations in the BMPR1A gene in our proband’s family (21). The severity of disease in this family seemed more pronounced than in many others with germline BMPR1A mutations, as two affected individuals developed colon cancer, and one had gastric juvenile polyps, both of which are more check details common in JP patients with SMAD4 rather than BMPR1A mutations (22,23). Our case also contradicts previous studies in the sense that JPS is an autosomal dominant disorder, and inheritance of a single deleterious

allele is sufficient to cause the JP phenotype (21). Apart from their academic significance, genetic Inhibitors,research,lifescience,medical examinations are crucial in identifying children who are carriers but have no symptoms. In any case, a paradigm shift is indeed needed for autosomal dominantly inherited diseases such Inhibitors,research,lifescience,medical as JPS. Hamartomatous polyps are not benign lesions; thus, we need to provide more advanced carcinoma-prevention by endoscopy, invasive endoscopy, or

surgical methods which may give these patients the opportunity for a better quality life with a longer life-span. Acknowledgements We thank Professor Istvan Ember (Medical University of Pecs, Hungary) Inhibitors,research,lifescience,medical for tumor marker analysis, Professor Istvan Racz (Petz Aladár Teaching Hospital of Győr, Hungary) for performing capsule endoscopy, and James R. Howe (University of Iowa Carver College of Medicine, Iowa City, IA, USA) for the genetic testing. Disclosure: The authors declare no conflict of interest.
Esophageal cancer is diagnosed in about 400,000 patients each year worldwide, and its incidence is increasing Inhibitors,research,lifescience,medical (1), it is the sixth leading cause of death from cancer (2). In

Europe, while incidence of SCC has remained stable or declined during the past few decades, the incidence of esophageal adenocarcinoma has been rising. This increase has been more prominent in Northern Europe, notably in the United Kingdom and Ireland (3,4). The majority of the patients suffering from a cancer Inhibitors,research,lifescience,medical of the esophagus presents with symptoms of dysphagia and weight loss because of an obstructive tumor (5). Several management options have been developed to palliate malignant dysphagia. These include endoluminal stenting Edoxaban or surgery and external beam radiation, brachytherapy, chemotherapy, chemoradiotherapy, laser treatment, photodynamic therapy or ablation using injection of alcohol or chemotherapeutic agents (6-8). Placement of self-expanding metallic stents (SEMS) made up of an alloy, usually nitinol or stainless steel, and deployed using endoscopic or fluoroscopic techniques, is a newer method for relief of dysphagia in these patients (9). External beam radiotherapy (EBRT) is known to provide durable and effective relief of dysphagia. However, there is a time lag before symptomatic relief occurs, and up to 6 weeks are required for maximum benefit (8).